Selvita, one of the largest preclinical contract research organizations in Europe, signed an agreement with the General Contractor – PORR S.A., which will be responsible for its construction.
The new facility will add much needed research capacity and allow for scale-up of business operations as well as expansion of services offer.
The total net value of contract amounts to EUR 19.1 million. The completion of the construction is expected at the turn of 2022/23. Selvita Research Centre will be created in the neighborhood of the current company HQ. At the heart of the new Selvita facility will be an array of laboratories incl. medicinal chemistry, biochemistry, cell & molecular biology, ADME/DMPK, in vivo pharmacology and analytical chemistry. The new facility will have a potential to accommodate approximately 250 employees.
“Our goal is to continuously grow and strengthen our position on the global CRO market. Expansion of our laboratory infrastructure and scope of services will bring us closer to achieving it. (…)” comments Dariusz Kurdas, Chief Financial Officer at Selvita.